Psyence Biomedical Ltd. Files Investor Presentation 6-K

Ticker: PBMWW · Form: 6-K · Filed: Aug 30, 2024 · CIK: 1985062

Sentiment: neutral

Topics: investor-relations, filing, presentation

TL;DR

Psyence Biomedical Ltd. just dropped an investor deck via 6-K, get ready for some investor calls.

AI Summary

Psyence Biomedical Ltd. filed a Form 6-K on August 30, 2024, to report an investor presentation. This presentation is intended for use by management in discussions with investors.

Why It Matters

This filing indicates that Psyence Biomedical Ltd. is actively engaging with investors, potentially signaling upcoming strategic discussions or financial updates.

Risk Assessment

Risk Level: low — The filing is a standard procedural document (Form 6-K) for an investor presentation and does not contain new material financial or operational information that would inherently increase risk.

Key Players & Entities

FAQ

What is the purpose of the Form 6-K filed by Psyence Biomedical Ltd. on August 30, 2024?

The Form 6-K was filed to report an investor presentation that management intends to use in discussions with investors.

What is the Commission File Number for this filing?

The Commission File Number is 001-41937.

What is the principal executive office address of Psyence Biomedical Ltd.?

The principal executive office is located at 121 Richmond Street West Penthouse Suite 1300, Toronto, Ontario M5H 2K1.

Does Psyence Biomedical Ltd. file annual reports under Form 20-F or Form 40-F?

Psyence Biomedical Ltd. indicates it files annual reports under cover of Form 20-F.

What is the SIC code for Psyence Biomedical Ltd.?

The Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.

Filing Stats: 262 words · 1 min read · ~1 pages · Grade level 10.8 · Accepted 2024-08-30 16:06:15

Filing Documents

From the Filing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 Commission File Number: 001-41937 Psyence Biomedical Ltd. (Translation of registrant’s name into English) 121 Richmond Street West Penthouse Suite 1300 Toronto, Ontario M5H 2K1 (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F x Form 40-F ¨ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨ Explanatory Note Psyence Biomedical Ltd. (the “Company”) has prepared an investor presentation (the “Investor Presentation”) that management intends to use with its presentation at the H.C. Wainwright 26 th Annual Global Investment Conference to be held on September 9 - 11, 2024. A copy of the Investor Presentation has been posted to the Company’s website and is furnished as Exhibit 99.1 hereto. Exhibits Exhibit Number Description 99.1 Investor Presentation, dated September 2024. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Dated: August 30, 2024 Psyence Biomedical Ltd. By: /s/ Dr. Neil Maresky Name: Dr. Neil Maresky Title: Chief Executive Officer and Director

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing